Source: European Medicines Agency (EU) Revision Year: 2024 Publisher: GlaxoSmithKline Trading Services Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
Dectova 10 mg/mL solution for infusion.
| Pharmaceutical Form |
|---|
|
Solution for infusion. A clear, colourless solution for infusion. |
Each mL of solution contains 10 mg of zanamivir (as hydrate).
Each vial contains 200 mg of zanamivir (as hydrate) in 20 mL.
Excipients with known effect:
Each vial contains 3.08 mmol (70.8 mg) sodium.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Zanamivir |
Zanamivir is an inhibitor of influenza virus neuraminidase, an enzyme that releases viral particles from the plasma membrane of infected cells and promotes virus spread in the respiratory tract. The activity of zanamivir is extracellular. It reduces the propagation of both influenza A and B viruses by inhibiting the release of infectious influenza virions from the epithelial cells of the respiratory tract. |
| List of Excipients |
|---|
|
Sodium chloride |
26 mL clear vial (type I glass) with a stopper (coated chlorobutyl rubber), an over-seal (aluminium) and a plastic flip-off cap.
Pack size: 1 vial.
GlaxoSmithKline Trading Services Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
EU/1/18/1349/001
Date of first authorisation: 26 April 2019
| Drug | Countries | |
|---|---|---|
| DECTOVA | Austria, Estonia, Finland, France, Croatia, Ireland, Lithuania, Netherlands, Poland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
